Prevalence of anti-PF4/heparin Antibodies and the HIT Syndrome in cardiovascular medicine

Seminars in Thrombosis and Hemostasis

Volumn 30, Issue 3, 2004, Pages 291-295

  Mattioli, Anna Vittoria ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Anticoagulation; Cardiac surgery; Heparin induced thrombocytopenia; HIT; LMWH; Low molecular weight heparin; Pathophysiology

Indexed keywords

ANTICOAGULANT AGENT; ANTIGEN; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CARDIOVASCULAR AGENT; DANAPAROID; GLYCOSAMINOGLYCAN; HEPARIN; HEPARINOID; HIRUDIN; IMMUNOGLOBULIN G ANTIBODY; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBOCYTE FACTOR 4;

ANTICOAGULANT THERAPY; CARDIOPULMONARY BYPASS; CLINICAL FEATURE; CLINICAL TRIAL; ENDOTHELIUM; HALF LIFE TIME; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE COUNT; THROMBOCYTE MEMBRANE; THROMBOCYTOPENIA; THROMBOSIS;

ADULT; ANTIBODIES; ANTICOAGULANTS; AUTOANTIBODIES; BLOOD PLATELETS; CHILD; DIAGNOSIS; ENDOTHELIUM, VASCULAR; HEART DISEASES; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; IMMUNOGLOBULIN G; PLATELET COUNT; PLATELET FACTOR 4; SYNDROME; THROMBOCYTOPENIA;

EID: 3843115532     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-831041     Document Type: Review

References (42)

1. Warkentin TE, Chong BH, Greinnacher A. Heparin induced thrombocytopenia. Toward consensus. Thromb Haemost 1998;79:1-7
2. Fabris F, Ahmad S, Cella G, Jeske WP, Walenga JM, Fareed J. Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications - review. Arch Pathol Lab Med 2000;124:1657-1666
3. Warkentin TE, Sheppard JI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96: 1703-1708
4. Chong BH, Grace CS, Rozenberg MC. Heparin-induced thrombocytopenia: effect of heparin platelet antibody on platelets. Br J Haematol 1981;49:531-540
5. Amiral J, Bridey F, Wolf M, et al. Antibodies to macromolecular platelet factor-4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost 1995;73:21-28
6. Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000;96:182-187
7. Horne KM, Hutchinson KJ. Simultaneous binding of heparin and platelet factor-4 to platelets: further insights into mechanism of heparin-induced thrombocytopenia. Am J Hematol 1998;58:24-30
8. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135:502-506
9. Lee DH, Warkentin TE, Denomme GA, Hayward CP, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. Br J Haematol 1996;95:724-731
10. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986;67:27-30
11. Greinacher A, Amiral J, Dummel V, Kiefel V, Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994;34:381-385
12. Amiral J, Fareed J. Thromboembolic diseases: biochemical mechanisms and new possibilities of biological diagnosis. Semin Thromb Hemost 1996;22:41-48
13. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:505-527
14. Warkentin T. Heparin induced thrombocytopenia; a ten-year retrospective. Annu Rev Med 1999;50:129-147
15. Warkentin TE, Kelton JG. Interaction of heparin with platelets including heparin-induced thrombocytopenia. In: Bounameaux H. ed. Low Molecular Weight Heparins in Prophylaxis and Therapy of Thromboembolic Diseases: Fundamental and Clinical Cardiology. New York: Marcel Dekker; 1994:75-127
16. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335
17. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin. Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1998;114:489S-510S
18. Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson LE, Greinacher A. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 2002;122:37-42
19. Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced Thrombocytopenia. 2nd ed. New York: Marcel Dekker; 2001:87-121
20. Francis JL, Palmer GJ III, Morose R, Drexler A. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg 2003;75:17-22
21. Mattioli AV, Bonetti L, Sternieri S, Mattioli G. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Ital Heart J 2000;1:39-42
22. Warkentin TE, Levine MN, Hirsh J, et al. Formation of heparin-induced thrombocytopenia IgG without thrombocytopenia: analysis of a clinical trial [abstract]. Blood 1995; 56:537a
23. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003;76:638-648
24. Greinacher A. Heparin-induced thrombocytopenia - pathogenesis and treatment. Thromb Haemost 1999;82:148-156
25. Gruel Y, Lang M, Darnige L. Fatal effect of re-exposure to heparin after previous heparin-associated thrombocytopenia and thrombosis. Lancet 1990;336:1077-1078
26. Elalamy I, Potevin F, Lecrubier C, Bara L, Marie J, Samama M. A fatal low-molecular weight heparin associated thrombocytopenia after hip surgery: possible usefulness of PF4-heparin ELISA test. Blood Coagul Fibrinolysis 1996;7:665-671
27. Andrew M. Development haemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995;74:415-425
28. Cella G, Vittadello O, Galucci V, Girolami A. The release of beta thromboglobulin and platelet factor 4 during extracorporeal circulation for open heart surgery. Eur J Clin Invest 1981;11:165-169
29. Singer IO, Sefcick A, Tait RC, Lindsay KW, Walker ID. Antithrombin concentrate alone may not prevent venous thromboembolism following neurosurgery. Br J Haematol 1998;103:583-584
30. Heck HA Jr, Lutcher CL, Falls DG. Fatal thrombocytopenic coagulopathy after cardiopulmonary bypass: clinicopathologic correlations implicating heparin. South Med J 1994;87:789-793
31. Trossaert M, Gaillard A, Commin PL, Amiral J, Vissac AM, Frassinaud E. High incidence of anti-heparin/platelet factor 4 antibodies after cardio-pulmonary bypass surgery. Br J Haematol 1998;101:653-655
32. Bauer TL, Arepally G, Konkle BA, et al. Prevalence of heparin associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997;95:1242-1246
33. Konkle BA, Bauer TL, Arepally G, et al. Heparin-induced thrombocytopenia: bovine versus porcine heparin in cardiopulmonary bypass surgery. Ann Thorac Surg 2001;71:1920-1924
34. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003;2:148-157
35. Walls JT, Curtis JJ, Silver D, Boley TM, Schmaltz RA, Nawarawong W. Heparin-induced thrombocytopenia in open heart surgical patients: sequelae of late recognition. Ann Thorac Surg 1992;53:787-791
36. Visentin GP, Malik MI, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin-platelet factor 4 complexes. J Lab Clin Med 1996;128:376-383
37. Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997;127:804-812
38. Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation 2001;103:1479-1484
39. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of two prospective trials to assess the value of patenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-851
40. Gillis S, Merin G, Zahger D, et al. Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia. Br J Haematol 1997;98:657-659
41. Warkentin TE. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res 2003;110:73-82
42. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163:1849-1856